The findings contradict last year's boxed warning that the US Food and Drug Administration mandated on the drug's label.
The label cautions that the drug has diminished effectiveness in poor metabolizers and may lead to an increase in cardiovascular events like heart disease or bleeding.
Yet, in the analysis published in the Journal of American Medical Association, researchers concluded that Plavix works well in patients both with and without the genotype.
Scientists looked at 32 studies involving more than 42,000 patients.
